文献速递心律失常

贫血对房颤患者口服抗凝疗效与安全性的影响

Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study.
PubMed 文献 · Eur Heart J · 2019-01-01

中重度贫血与重大出血风险增加及TTR降低相关;口服抗凝在无贫血或轻度贫血患者中降低卒中/血栓栓塞风险,但在中重度贫血患者中未降低卒中风险且增加重大出血风险。

要点

  • 房颤患者中贫血常见,中重度贫血与重大出血风险增加相关
  • 中重度贫血患者口服抗凝未降低卒中/血栓栓塞风险
  • 中重度贫血患者口服抗凝增加重大出血的绝对风险

核心结论

  • 贫血在房颤患者中常见,与重大出血和较低TTR相关
  • 中重度贫血患者口服抗凝未降低卒中/血栓栓塞风险,反而增加重大出血风险

研究设计与样本

  • 基于丹麦行政登记数据库的观察性队列研究

主要发现

  • 3796例(20%)为轻度贫血,2562例(14%)为中重度贫血
  • 中重度贫血与重大出血风险增加及中位TTR降低9.1%相关
  • 口服抗凝在无贫血患者中降低卒中/血栓栓塞的标准化绝对1年差异为-2.5%(95%CI -3.8至-1.7%)
  • 口服抗凝在轻度贫血患者中降低卒中/血栓栓塞的标准化绝对1年差异为-2.3%(95%CI -2.8至-1.8%)
  • 口服抗凝在中重度贫血患者中未降低卒中/血栓栓塞风险(0.03%,95%CI -1.8至+2.8%,交互P=0.01),且增加重大出血的标准化绝对风险5.3%(95%CI 2.1-8.7%)

临床怎么用

  • 对房颤合并中重度贫血患者,处方口服抗凝需权衡出血风险与卒中预防获益

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To investigate the risk of stroke/thromboembolism (TE) and major bleeding associated with anaemia among patients with atrial fibrillation (AF). Also, to assess the effects of oral anticoagulation (OAC) and time in therapeutic range (TTR) with vitamin K antagonists according to level of haemoglobin (Hb). METHODS AND RESULTS: Through administrative registry databases, we identified all Danish patients diagnosed with AF from 1997 to 2012. We included 18 734 AF patients with recent available data on Hb. Multiple Cox regression analyses were used to estimate hazard ratios and to compute standardized absolute 1-year risks of stroke/TE and major bleeding. Among included patients, 3796 (20%) had mild anaemia (Hb 6.83-7.45 mmol/L for women and Hb 6.83-8.03 mmol/L for men) and 2562 (14%) had moderate/severe anaemia (Hb <6.83 mmol/L). Moderate/severe anaemia was associated with increased risk of major bleeding and 9.1% lower median TTR compared with no anaemia. Use of OAC was associated with reduced risk of stroke/TE among patients without anaemia [standardized absolute 1-year difference -2.5%, 95% confidence interval (CI) -3.8 to -1.7%] or with mild anaemia (-2.3%, 95% CI -2.8 to -1.8%), but not with moderate/severe anaemia, (0.03%, -1.8 to +2.8%, interaction P = 0.01). Oral anticoagulation was associated with a 5.3% (95% CI 2.1-8.7%) increased standardized absolute risk of major bleeding among AF patients with moderate/severe anaemia. CONCLUSION: Anaemia was common in patients with AF and associated with major bleeding and lower TTR. Oral anticoagulation was associated with more major bleeding, but no reduction in risk of stroke/TE among AF patients with moderate/severe anaemia.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Bonde AN, Blanche P, Staerk L, et al. Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study. Eur Heart J. 2019. PMID: 30932145. doi:10.1093/eurheartj/ehz155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。